A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

NCT06868485 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: WSD0922-FU Tablets, Dose level A
DRUG: WSD0922-FU Tablets, Dose level B

Sponsor

Wayshine Biopharm, Inc.